论文部分内容阅读
目的:观察腹腔内灌注三氧水对癌性腹腔积液的临床效果以及对患者生活质量的影响。方法:选择我院2015年10月-2016年12月收治的25例癌性腹腔积液患者为研究对象,随机分为两组,实验组10例引流后给予三氧水腹腔灌注,每次灌注量为200mL,每日1次,7天为1疗程,对照组15例给予放腹水联合间断输注血浆白蛋白利尿治疗,治疗后评价和比较两组的疗效、生活质量的改善情况及不良反应的发生情况。结果:实验组完全缓解2例,部分缓解5例,稳定2例,无效1例,总有效率90%;对照组完全缓解3例,部分缓解8例,稳定2例,无效2例,总有效率86.6%,实验组总有效率显著高于对照组(P=0.029)。实验组QOL改善稳定率90%,对照组QOL改善稳定率66.6%,两组差异有统计学意义(P=0.017)。两组不良反应的发生情况比较,差异无统计学意义(P>0.05)。结论:三氧水灌注引流治疗癌性腹腔积液可以更有效地提高晚期肿瘤患者的生活质量。
Objective: To observe the clinical effect of intraperitoneal perfusion of three oxygenated water on patients with malignant ascites and the impact on quality of life of patients. Methods: Twenty-five patients with cancerous ascitic fluid admitted from October 2015 to December 2016 in our hospital were selected and randomly divided into two groups. In the experimental group, 10 patients were treated with intraperitoneal perfusion of trichlorohydrin after drainage, The amount of 200mL, 1 day, 7 days for a course of treatment, the control group of 15 patients given ascites combined with intermittent infusion of plasma albumin diuretic treatment, evaluation and comparison of the two groups after treatment efficacy, quality of life improvement and adverse reactions The occurrence of. Results: The experimental group completely relieved in 2 cases, partial remission in 5 cases, stable in 2 cases, ineffective in 1 case, the total effective rate was 90%; control group, complete remission in 3 cases, partial remission in 8 cases, stable in 2 cases, ineffective in 2 cases, The efficiency was 86.6%. The total effective rate in experimental group was significantly higher than that in control group (P = 0.029). The improvement rate of QOL in the experimental group was 90%, while that of the control group was 66.6%. The difference between the two groups was statistically significant (P = 0.017). There was no significant difference in the occurrence of adverse reactions between the two groups (P> 0.05). Conclusion: The treatment of malignant ascites with infusion of trichloro-water can improve the quality of life of patients with advanced cancer more effectively.